{"component": "definition", "props": {"groups": [{"samples": [{"hash": "iM3a9DE1nqZ", "uri": "/contracts/iM3a9DE1nqZ#option-technology", "label": "Option Agreement (Octillion Corp)", "score": 21.0, "published": true}, {"hash": "hFmrENcZZf4", "uri": "/contracts/hFmrENcZZf4#option-technology", "label": "Option Agreement (Microchannel Technologies Corp)", "score": 21.0, "published": true}, {"hash": "dvSuV7aX5t9", "uri": "/contracts/dvSuV7aX5t9#option-technology", "label": "Option Agreement (Octillion Corp)", "score": 21.0, "published": true}], "snippet_links": [{"key": "refer-to", "type": "definition", "offset": [6, 14]}, {"key": "the-intellectual-property", "type": "clause", "offset": [24, 49]}, {"key": "docket-number", "type": "definition", "offset": [139, 152]}, {"key": "patents-and-patent-applications", "type": "clause", "offset": [174, 205]}, {"key": "appendix-a", "type": "clause", "offset": [216, 226]}, {"key": "option-territory", "type": "clause", "offset": [263, 279]}, {"key": "owned-by", "type": "definition", "offset": [319, 327]}, {"key": "to-the-extent", "type": "clause", "offset": [380, 393]}], "size": 4, "snippet": "shall refer to and mean the intellectual property entitled \u201cPatterned Substrates and Methods for Nerve Regeneration\u201d as described in ISURF Docket Number 02610, including any patents and patent applications listed on Appendix A hereto that are in countries in the Option Territory and any subsequent patent applications owned by ISURF in a country in the Option Territory but only to the extent it claims an invention claimed in a patent application listed on Appendix A in such country.", "hash": "f598eca255cc29c297b84dd2c9ff5503", "id": 1}, {"samples": [{"hash": "8M7c9czbGhx", "uri": "/contracts/8M7c9czbGhx#option-technology", "label": "Collaboration and Option Agreement (Iambic Therapeutics, Inc.)", "score": 37.720054757, "published": true}, {"hash": "kNldsGbllZA", "uri": "/contracts/kNldsGbllZA#option-technology", "label": "Collaboration and Option Agreement (Iambic Therapeutics, Inc.)", "score": 37.6543463381, "published": true}], "snippet_links": [{"key": "option-patents", "type": "definition", "offset": [10, 24]}], "size": 3, "snippet": "means the Option Patents and Option Know-How.", "hash": "e36eee03618f49cb4a4d40d7df761b4b", "id": 2}, {"samples": [{"hash": "lKoFlaoQxoc", "uri": "/contracts/lKoFlaoQxoc#option-technology", "label": "Joint Research, Development and License Agreement (Cephalon Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "institute-inventions", "type": "definition", "offset": [38, 58]}, {"key": "patent-rights", "type": "clause", "offset": [94, 107]}, {"key": "outside-of-the-field", "type": "clause", "offset": [117, 137]}, {"key": "the-research-program", "type": "clause", "offset": [214, 234]}, {"key": "the-institute", "type": "definition", "offset": [268, 281]}, {"key": "commercial-relationship", "type": "clause", "offset": [327, 350]}, {"key": "patent-applications", "type": "clause", "offset": [356, 375]}, {"key": "relate-to", "type": "definition", "offset": [392, 401]}, {"key": "subject-matter", "type": "definition", "offset": [406, 420]}, {"key": "family-members", "type": "definition", "offset": [630, 644]}, {"key": "discoveries-and-inventions", "type": "clause", "offset": [739, 765]}, {"key": "for-example", "type": "clause", "offset": [808, 819]}, {"key": "not-limited", "type": "clause", "offset": [856, 867]}, {"key": "application-no", "type": "clause", "offset": [1116, 1130]}, {"key": "confidential-material", "type": "clause", "offset": [1138, 1159]}, {"key": "the-commission", "type": "clause", "offset": [1229, 1243]}], "size": 1, "snippet": "means:\n(1) all Institute Discoveries, Institute Inventions, Institute Know-How, and Institute Patent Rights that are outside of the Field; and\n(2) all Institute discoveries, inventions and know-how made outside of the Research Program as set forth in the LSRA between the Institute and Cephalon, not committed to a third-party commercial relationship, and patent applications or patents that relate to the subject matter of the Research Program as set forth in the LSRA, between the Institute and Cephalon, such as receptors for GDNF, Neurturin, Persefin, and their homologs (hereafter GDNF family), ligands of receptors for GDNF family members and components of the signaling cascade for GDNF family receptors, regardless of whether such discoveries and inventions are inside or outside of the Field. Thus, for example, Option Technology includes, but is not limited to, the discovery and/or characterization of ligands that interact with GDNF, GDNF receptors or GDNF-related receptors, including Drosophila ligands and vertebrate and invertebrate homologs of such invertebrate ligands as embodied in a Provisional Application No. [*The confidential material contained herein has been omitted and has been separately filed with the Commission.]", "hash": "55c555c094d570400a0b7048e31f67b0", "id": 3}, {"samples": [{"hash": "cVzlkyjnGAj", "uri": "/contracts/cVzlkyjnGAj#option-technology", "label": "Collaboration & License Agreement (Immatics B.V.)", "score": 31.2888431549, "published": true}], "snippet_links": [{"key": "as-of-the-effective-date", "type": "clause", "offset": [61, 85]}, {"key": "during-the-term", "type": "clause", "offset": [89, 104]}, {"key": "relating-to", "type": "definition", "offset": [105, 116]}, {"key": "exhibit-f", "type": "definition", "offset": [147, 156]}, {"key": "at-any-time", "type": "clause", "offset": [239, 250]}], "size": 1, "snippet": "means: (a) any Information that is Controlled by MD \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 as of the Effective Date or during the Term relating to the technologies set forth on Exhibit F; and (b) any Patent that is Controlled by MD \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 as of the Effective Date or at any time during the Term that claims or covers the technologies set forth on Exhibit F.", "hash": "a3a90ee0eb01521964b2ae788ca51171", "id": 4}, {"samples": [{"hash": "1GSsolCxssC", "uri": "/contracts/1GSsolCxssC#option-technology", "label": "Option Agreement", "score": 26.1704311371, "published": true}], "snippet_links": [{"key": "refer-to", "type": "definition", "offset": [6, 14]}, {"key": "the-intellectual-property", "type": "clause", "offset": [24, 49]}, {"key": "docket-number", "type": "definition", "offset": [85, 98]}, {"key": "patents-and-patent-applications", "type": "clause", "offset": [115, 146]}, {"key": "appendix-a", "type": "clause", "offset": [157, 167]}, {"key": "option-territory", "type": "clause", "offset": [204, 220]}, {"key": "owned-by", "type": "definition", "offset": [260, 268]}, {"key": "to-the-extent", "type": "clause", "offset": [321, 334]}, {"key": "relating-to", "type": "definition", "offset": [509, 520]}, {"key": "effective-date-of-this-agreement", "type": "definition", "offset": [593, 625]}], "size": 1, "snippet": "shall refer to and mean the intellectual property entitled \u201c \u201d as described in ISURF Docket Number , including any patents and patent applications listed on Appendix A hereto that are in countries in the Option Territory and any subsequent patent applications owned by ISURF in a country in the Option Territory but only to the extent it claims an invention claimed in a patent application listed on Appendix A in such country. [If appropriate: Option Technology shall also include any technique and know-how relating to the inventions of the Option Technology and assigned to ISURF as of the effective date of this Agreement.]", "hash": "e470274306103dd2077e0f68b4bfb398", "id": 5}, {"samples": [{"hash": "iJpNd5HlZ1C", "uri": "/contracts/iJpNd5HlZ1C#option-technology", "label": "Exclusive License Agreement (Sarepta Therapeutics, Inc.)", "score": 34.5824775696, "published": true}], "snippet_links": [{"key": "patent-rights", "type": "clause", "offset": [10, 23]}, {"key": "the-technology", "type": "definition", "offset": [25, 39]}, {"key": "product-ind", "type": "definition", "offset": [56, 67]}], "size": 1, "snippet": "means the Patent Rights, the Technology, and the Option Product IND.", "hash": "3b51f250652fe38a97f2367b909f51d9", "id": 6}, {"samples": [{"hash": "7nBzPybNABL", "uri": "/contracts/7nBzPybNABL#option-technology", "label": "Development and License Agreement (Cardiac Science Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "section-61", "type": "clause", "offset": [36, 47]}], "size": 1, "snippet": "shall have the meaning set forth in Section 6.1.", "hash": "2229502a089620533cc7bc2af548986c", "id": 7}, {"samples": [{"hash": "48mNs3QhRDA", "uri": "/contracts/48mNs3QhRDA#option-technology", "label": "Option Agreement", "score": 29.6747169495, "published": true}], "snippet_links": [{"key": "patents-and-patent-applications", "type": "clause", "offset": [17, 48]}, {"key": "appendix-a", "type": "clause", "offset": [59, 69]}, {"key": "claiming-priority", "type": "clause", "offset": [110, 127]}, {"key": "reexamination-and-reissue", "type": "clause", "offset": [205, 230]}, {"key": "term-extensions", "type": "clause", "offset": [248, 263]}, {"key": "owned-by", "type": "definition", "offset": [347, 355]}, {"key": "each-case", "type": "definition", "offset": [375, 384]}, {"key": "to-the-extent", "type": "clause", "offset": [393, 406]}, {"key": "subject-matter", "type": "definition", "offset": [414, 428]}], "size": 1, "snippet": "means: (i) those patents and patent applications listed on Appendix A attached hereto, any patent application claiming priority thereto, including divisionals and continuations, patents issuing therefrom, reexamination and reissue patents thereof, term extensions thereof and supplemental protection certificate thereon; and (ii) which are solely owned by ISURF, but only in each case, solely to the extent of the subject matter claimed that is sufficiently disclosed in a patent application listed on Appendix A to satisfy 35 U.S.C. \u00a7112.", "hash": "30c27da43e554fc833abcb8d519b7241", "id": 8}, {"samples": [{"hash": "uneOWUoLZU", "uri": "/contracts/uneOWUoLZU#option-technology", "label": "Settlement Agreement (Ligand Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "by-employees", "type": "clause", "offset": [46, 58]}, {"key": "including-without-limitation", "type": "clause", "offset": [112, 140]}, {"key": "technical-data", "type": "definition", "offset": [142, 156]}, {"key": "to-practice", "type": "clause", "offset": [313, 324]}, {"key": "an-act", "type": "definition", "offset": [370, 376]}, {"key": "claims-of", "type": "clause", "offset": [409, 418]}, {"key": "patented-technology", "type": "definition", "offset": [448, 467]}, {"key": "not-employees", "type": "clause", "offset": [617, 630]}, {"key": "research-collaborators", "type": "definition", "offset": [678, 700]}, {"key": "pursuant-to-section", "type": "definition", "offset": [717, 736]}], "size": 1, "snippet": "means any invention, discovery or development by employees, consultants or agents of one or more of DEFENDANTS, including without limitation, technical data, specifications, information, know-how, processes, compounds, formulations and materials, which invention, discovery or development was enabled by, reduced to practice, or otherwise derived from or facilitated by an act or acts within the scope of the claims of any patent within the Ligand Patented Technology. Option Technology also includes inventions, discoveries or developments made by employees, consultants or agents of DEFENDANTS with persons who are not employees, consultants or agents of DEFENDANTS including Research Collaborators with DEFENDANTS pursuant to Section 5.02 hereof.", "hash": "8441e9d6825bc546a8dd5046185e25b3", "id": 9}, {"samples": [{"hash": "1GSsolCxssC", "uri": "/contracts/1GSsolCxssC#option-technology", "label": "Option Agreement", "score": 26.1704311371, "published": true}], "snippet_links": [{"key": "refer-to", "type": "definition", "offset": [6, 14]}, {"key": "the-intellectual-property", "type": "clause", "offset": [24, 49]}, {"key": "docket-number", "type": "definition", "offset": [85, 98]}, {"key": "intellectual-property-rights", "type": "clause", "offset": [109, 137]}, {"key": "option-territory", "type": "clause", "offset": [215, 231]}, {"key": "with-respect-to", "type": "clause", "offset": [232, 247]}, {"key": "trade-secrets", "type": "definition", "offset": [281, 294]}, {"key": "computer-software", "type": "definition", "offset": [299, 316]}], "size": 1, "snippet": "shall refer to and mean the intellectual property entitled \u201c \u201d as described in ISURF Docket Number , and any intellectual property rights thereto, including any rights arising under any laws in the countries of the Option Territory with respect to patents, copyrights, trademarks, trade secrets and computer software.]", "hash": "f90906a5a3b910fb56da085d04fc3c38", "id": 10}], "next_curs": "Cl4SWGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjoLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIab3B0aW9uLXRlY2hub2xvZ3kjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Option Technology", "size": 15, "snippet": "shall refer to and mean the intellectual property entitled \u201cPatterned Substrates and Methods for Nerve Regeneration\u201d as described in ISURF Docket Number 02610, including any patents and patent applications listed on Appendix A hereto that are in countries in the Option Territory and any subsequent patent applications owned by ISURF in a country in the Option Territory but only to the extent it claims an invention claimed in a patent application listed on Appendix A in such country.", "id": "option-technology", "examples": ["Upon any bankruptcy of Iambic, Lundbeck will further be entitled to a complete duplicate of, or complete access to, any such <strong>Option Technology</strong> not already in its possession, and such intellectual property will be promptly delivered to Lundbeck, unless Iambic elects in writing to continue, and continues, to perform all its obligations under this Agreement.", "Effective on the Option Exercise Date, (a) Iambic shall grant and hereby grants to Lundbeck and its Affiliates an exclusive, royalty-bearing license, including the right to grant and authorize sublicenses (subject to Section 5.5), under the <strong>Option Technology</strong> and (b) [***], in each case (a) and (b) solely to Exploit the Option Products in the Territory within the Field ((a) and (b) collectively, the \u201cCommercial License\u201d) for the duration of the Term.", "For the duration of the Commercial License, Iambic shall not use the <strong>Option Technology</strong> to Exploit the Option Products within or outside the Field, including by granting licenses to the <strong>Option Technology</strong> to Exploit the Option Products to any Third Party.", "Such cooperation will include providing Lundbeck with reasonable access by teleconference or in-person at Iambic\u2019s facilities to appropriate personnel from Iambic to provide Lundbeck with a reasonable level of technical assistance and consultation in connection with the transfer of <strong>Option Technology</strong> pursuant to the Transition Plan."], "related": [["collaboration-technology", "Collaboration Technology", "Collaboration Technology"], ["information-technology", "Information Technology", "Information Technology"], ["information-technologies", "Information Technologies", "Information Technologies"], ["communication-technology", "Communication technology", "Communication technology"], ["information-technology-systems", "Information Technology Systems", "Information Technology Systems"]], "related_snippets": [], "updated": "2026-09-23T06:37:02+00:00"}, "json": true, "cursor": ""}}